- Home
- ACIU vs RBB Comparison
ACIU vs RBB Comparison
Compare ACIU & RBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- RBB
- Stock Information
- Founded
- ACIU 2003
- RBB 2008
- Country
- ACIU Switzerland
- RBB United States
- Employees
- ACIU N/A
- RBB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- RBB Major Banks
- Sector
- ACIU Health Care
- RBB Finance
- Exchange
- ACIU Nasdaq
- RBB Nasdaq
- Market Cap
- ACIU 247.4M
- RBB 292.5M
- IPO Year
- ACIU 2016
- RBB 2017
- Fundamental
- Price
- ACIU $1.48
- RBB $15.08
- Analyst Decision
- ACIU Strong Buy
- RBB Hold
- Analyst Count
- ACIU 2
- RBB 4
- Target Price
- ACIU $12.00
- RBB $21.25
- AVG Volume (30 Days)
- ACIU 192.5K
- RBB 36.0K
- Earning Date
- ACIU 05-12-2025
- RBB 04-28-2025
- Dividend Yield
- ACIU N/A
- RBB 4.23%
- EPS Growth
- ACIU N/A
- RBB N/A
- EPS
- ACIU N/A
- RBB 1.47
- Revenue
- ACIU $30,136,397.00
- RBB $104,842,000.00
- Revenue This Year
- ACIU N/A
- RBB $14.95
- Revenue Next Year
- ACIU $676.94
- RBB $7.77
- P/E Ratio
- ACIU N/A
- RBB $10.45
- Revenue Growth
- ACIU 84.51
- RBB N/A
- 52 Week Low
- ACIU $1.43
- RBB $14.49
- 52 Week High
- ACIU $4.98
- RBB $25.30
- Technical
- Relative Strength Index (RSI)
- ACIU 24.24
- RBB 33.18
- Support Level
- ACIU $1.48
- RBB $14.62
- Resistance Level
- ACIU $1.62
- RBB $15.44
- Average True Range (ATR)
- ACIU 0.12
- RBB 0.72
- MACD
- ACIU -0.00
- RBB -0.03
- Stochastic Oscillator
- ACIU 9.43
- RBB 26.82
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About RBB RBB Bancorp
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.